A Phase I study of expanded and activated allogeneic gamma-delta T cells for patients with blood cancers following haploidentical stem cell transplantation.

Trial Profile

A Phase I study of expanded and activated allogeneic gamma-delta T cells for patients with blood cancers following haploidentical stem cell transplantation.

Planning
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Allogeneic-gamma-delta-T-cell-therapy (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Sep 2017 New trial record
    • 19 Sep 2017 According to an Incysus media release, company has submitted Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top